Advertisement

Product › Details
Ilaris®
![]() |
Next higher product group | canakinumab (ACZ885) |
![]() |
Status | 2013-09-30 registration start |
![]() |
Organisation | Novartis AG (NYSE: NVS) |
Group | Novartis (Group) | |
Record changed: 2023-07-10 |
Advertisement

More documents for therapeutic antibody
- [1] Calluna Pharma AS. (10/9/24). "Press Release: Calluna Pharma Appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board". Oslo & Boston, MA....
- [2] Yumab GmbH. (10/8/24). "Press Release: Yumab and Molcure Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets"....
- [3] Epsilogen Ltd.. (9/9/24). "Press Release: Epsilogen Completes £12.5 Million Series B Financing Expansion". London....
- [4] SciRhom GmbH. (7/9/24). "Press Release: SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases". Munich....
- [5] InflaRx N.V.. (6/24/24). "Press Release: InflaRx’s Gohibic (vilobelimab) Selected for First BARDA-sponsored Clinical Trial to Evaluate Novel Host-directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)". Jena....
- [6] SciRhom GmbH. (6/12/24). "Press Release: SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases". Munich....
- [7] ProBioGen AG. (5/29/24). "Press Release: ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development". Berlin....
- [8] Adrenomed AG. (4/10/24). "Press Release: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock". Hennigsdorf....
- [9] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [10] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top